C Palmieri
Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer
Palmieri, C; Caley, M P; Purshouse, K; Fonseca, A-V; Rodriguez-Teja, M; Kogianni, G; Woodley, L; Odendaal, J; Elliott, K; Waxman, J; Sturge, Justin
Authors
M P Caley
K Purshouse
A-V Fonseca
M Rodriguez-Teja
G Kogianni
L Woodley
J Odendaal
K Elliott
J Waxman
Dr Justin Sturge J.Sturge@hull.ac.uk
Reader
Abstract
Background:Endo180 (CD280; MRC2; uPARAP)-dependent collagen remodelling is dysregulated in primary tumours and bone metastasis. Here, we confirm the release and diagnostic accuracy of soluble Endo180 for diagnosing metastasis in breast cancer (BCa).Methods:Endo180 was quantified in BCa cell conditioned medium and plasma from BCa patients stratified according to disease status and bisphosphonate treatment (n=88). All P-values are from two-sided tests.Results:Endo180 is released by ectodomain shedding from the surface of MCF-7 and MDA-MB-231 BCa cell lines. Plasma Endo180 was significantly higher in recurrent/metastatic (1.71±0.87; n=59) vs early/localised (0.92±0.37; n=29) BCa (P<0.0001). True/false-positive rates for metastasis classification were: 85%/50% for the reference standard, CA 15-3 antigen (28 U ml-1); 97%/36% for Endo180; and 97%/32% for CA 15-3 antigen+Endo180. Bisphosphonate treatment was associated with reduced Endo180 levels in BCa patients with bone metastasis (P=0.011; n=42). True/false-positive rates in bisphosphonate-naive patients (n=57) were: 68%/45% for CA 15-3 antigen; 95%/20% for Endo180; and 92%/21% for CA 15-3 antigen+Endo180.Conclusion:Endo180 is a potential marker modulated by bisphosphonates in metastatic BCa.
Citation
Palmieri, C., Caley, M. P., Purshouse, K., Fonseca, A.-V., Rodriguez-Teja, M., Kogianni, G., Woodley, L., Odendaal, J., Elliott, K., Waxman, J., & Sturge, J. (2013). Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer. The British Journal of Cancer, 108(1), 163-169. https://doi.org/10.1038/bjc.2012.540
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 31, 2013 |
Online Publication Date | Dec 20, 2012 |
Publication Date | 2013-01 |
Journal | British Journal of Cancer |
Print ISSN | 0007-0920 |
Electronic ISSN | 1532-1827 |
Publisher | Nature Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 108 |
Issue | 1 |
Pages | 163-169 |
DOI | https://doi.org/10.1038/bjc.2012.540 |
Keywords | Cancer Research; Oncology |
Public URL | https://hull-repository.worktribe.com/output/432500 |
You might also like
Endo180 at the cutting edge of bone cancer treatment and beyond
(2016)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search